Results 201 to 210 of about 2,114,568 (336)

Genética de Coffea XXIV - Mutantes de Coffea arabica procedemtes da Etiópia [PDF]

, 1959
Alcides Carvalho
openalex   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Correction: TSG101 depletion dysregulates mitochondria and PML NBs, triggering MAD2-overexpressing interphase cell death (MOID) through AIFM1-PML-DAXX pathway

Cell Death and Disease
Yao Xi, Rui Xu, Shengnan Chen, Jiezhu Fang, Xiang Duan, Yidan Zhang, Guoli Zhong, Zhifei He, Yan Guo, Xinyu Li, Wenzhi Tao, Yang Li, Yan Li, Lei Fang, Yohei Niikura   +14 more
doaj   +1 more source

Physiological and transcriptomic analyses reveal the mechanisms underlying leaf color variation in zebra-striped mutants of oat (Avena sativa). [PDF]

BMC Plant Biol
Lin D, Chai J, Zeng L, Niu K, Liu X, Ma Y, Zhao G.   +6 more
europepmc   +1 more source

A Haploid Mutant in the Jimson Weed, " Datura stramonium " [PDF]

, 1922
A. F. Blakeslee, John Belling, M. E. Farnham, A. Dorothy Bergner   +3 more
openalex   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Characterization of phenotypic and genetic diversity in sodium azide-induced mutant populations in oat (Avena sativa). [PDF]

BMC Plant Biol
Lin D, Chai J, Zeng L, Wang W, Gong W, Su W, Liu X, Zhao G.   +7 more
europepmc   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Extensive cross-reactive T cell epitopes across SARS-CoV-2 Omicron variant spikes with finite immune evasion mutations. [PDF]

J Transl Med
Gan M, Cao J, Ouyang Q, Xu X, Wang X, Dan P, Yao Y, Fu H, Yao X, Lin X, Lei Q, Fan X.   +11 more
europepmc   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source